Immunological activity in the CNS is largely dependent on an innate immune response and is heightened in diseases, such as diabetic retinopathy, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. The molecular dynamics governing immune cell recruitment to sites of injury and disease in the CNS during sterile inflammation remain poorly defined. Here, we identified a subset of mononuclear phagocytes (MPs) that responds to local chemotactic cues that are conserved among central neurons, vessels, and immune cells. Patients suffering from late-stage proliferative diabetic retinopathy (PDR) had elevated vitreous semaphorin 3A (SEMA3A). Using a murine model, we found that SEMA3A acts as a potent attractant for neuropilin-1-positive (NRP-1-positive) MPs. These proangiogenic MPs were selectively recruited to sites of pathological neovascularization in response to locally produced SEMA3A as well as VEGF. NRP-1-positive MPs were essential for disease progression, as NRP-1-deficient MPs failed to enter the retina in a murine model of oxygen-induced retinopathy (OIR), a proxy for PDR. OIR mice with NRP-1-deficient MPs exhibited decreased vascular degeneration and diminished pathological preretinal neovascularization. Intravitreal administration of a NRP-1-derived trap effectively mimicked the therapeutic benefits observed in mice lacking NRP-1-expressing MPs. Our findings indicate that NRP-1 is an obligate receptor for MP chemotaxis, bridging neural ischemia to an innate immune response in neovascular retinal disease.
Introduction
The CNS had long been considered an immune-privileged system, yet it is now clear that the brain, retina, and spinal cord are subjected to complex immune surveillance (1, 2) . This is evident in the retina, in which an intensified, largely microglial/macrophage-based immune response is associated with the progression of several sight-threatening diseases, such as diabetic retinopathy (DR) (3) (4) (5) , age-related macular degeneration (AMD) (6) (7) (8) , and retinopathy of prematurity (ROP) (9, 10) . Together, these retinal diseases account for the principal causes of loss of sight in industrialized countries (6, 11, 12) .
A common etiology for blinding vasoproliferative retinopathies such as DR and ROP is the initial degeneration of retinal microvasculature, followed by ischemic stress on the neuroretina. This triggers a second phase of deregulated and destructive angiogenesis (13) . Given this sequence of events and prominent clinical features, the most widely used, current local ocular therapeutic interventions directly target pathological neovascularization yet present a number of nondesirable off-target effects. For example, front-line treatments, such as laser photocoagulation, which ablate ischemic retinal tissue with the aim of reducing production of angiogenic factors, compromise visual field and provoke scotomas. Moreover, given the neurosupportive properties of VEGF, a growing number of neurological and developmental side effects are being attributed to long-term intravitreal anti-VEGFs regimens (4, 11, (14) (15) (16) . Overcoming these therapeutic limitations or exploring novel pharmacological avenues is therefore required to ameliorate the safety profiles of current interventions. In this regard, there is increasing evidence for the breakdown of the neurovascular unit in proliferative retinopathies (4, 17, 18) . In particular, retinal ganglion cells and neurons of the inner nuclear layer that are in intimate contact with degenerating vasculature in DR and ROP (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI76492DS1) are subjected to various forms of cellular stress, including ER stress (19) , oxidative stress (13) , inflammatory stress (18) (19) (20) (21) , and increased microglial activity (22) (23) (24) (25) . Whether stressed or damaged central retinal neurons themselves have the propensity to modulate the immune response to reestablish local homeostasis, clear debris (2) , or segregate irreparably damaged tissue (17) is unknown and could provide therapeutic insight for designing targeted inhibitors of sterile neuroinflammation.
While a role for mononuclear phagocytes (MPs), such as microglia/macrophages, has been established in proliferative retinopathies (22) (23) (24) (25) , the local tissue-specific molecular cues and Immunological activity in the CNS is largely dependent on an innate immune response and is heightened in diseases, such as diabetic retinopathy, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. The molecular dynamics governing immune cell recruitment to sites of injury and disease in the CNS during sterile inflammation remain poorly defined. Here, we identified a subset of mononuclear phagocytes (MPs) that responds to local chemotactic cues that are conserved among central neurons, vessels, and immune cells. Patients suffering from late-stage proliferative diabetic retinopathy (PDR) had elevated vitreous semaphorin 3A (SEMA3A). Using a murine model, we found that SEMA3A acts as a potent attractant for neuropilin-1-positive (NRP-1-positive) MPs. These proangiogenic MPs were selectively recruited to sites of pathological neovascularization in response to locally produced SEMA3A as well as VEGF. NRP-1-positive MPs were essential for disease progression, as NRP-1-deficient MPs failed to enter the retina in a murine model of oxygeninduced retinopathy (OIR), a proxy for PDR. OIR mice with NRP-1-deficient MPs exhibited decreased vascular degeneration and diminished pathological preretinal neovascularization. Intravitreal administration of a NRP-1-derived trap effectively mimicked the therapeutic benefits observed in mice lacking NRP-1-expressing MPs. Our findings indicate that NRP-1 is an obligate receptor for MP chemotaxis, bridging neural ischemia to an innate immune response in neovascular retinal disease.
Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk described on microglia during vascular anastomosis (31) and recently described in tumor-associated macrophages with roles in vessel maturation (32) and proangiogenic properties (33) . Importantly, the physiological role of myeloid-resident NRP-1 remains unclear, particularly in the context of the CNS. We therefore sought to determine the function of myeloid-resident NRP-1 in the pathogenesis of proliferative retinopathies.
Here, we demonstrate that, via production of SEMA3A and VEGF, the ischemic neural retina has the inherent capacity to modulate the innate immune response by summoning circulating MPs to sites of vascular injury. We provide evidence in both human and animal studies for the critical role of myeloid-resident NRP-1 in the chemotaxis and accretion of MPs in proliferative retinopathies. Our findings further suggest that current anti-VEGF therapies may in part be effective by reducing destructive ocular inflammation.
Results

NRP-1 identifies a population of MPs that are mobilized secondary to vascular injury.
To determine whether MPs such as microglia or macrophages partake in the vascular pathogenesis associated with proliferative retinopathies, we first carried out FACS analysis on whole mouse retinas to elucidate the kinetics of macrophage/ microglial accumulation throughout the evolution of OIR (Figure 1A ) (75% oxygen from P7-P12 to induce vaso-obliteration and room air until P17 to attain maximal preretinal neovascularization) (refs. 26, 33 , and Figure 1 , B, E, and H). Our data revealed significantly higher numbers of retinal macrophage/microglial cells (Gr-1
+ cells) (gating scheme in Supplemental Figure 2 ) in OIR at all time points analyzed, including a 36% increase during the vaso-obliterative phase at P10 (P = 0.0004) ( Figure 1C ), a 63% rise during the neovascular phase at P14 (P < 0.0001) ( Figure 1F ), and a 172% surge during maximal neovascularization at P17 (P = 0.0006) ( Figure 1I ). These findings agree with the prevailing notion of microglial involvement in retinal neovascularization (22, 23, 34) . mechanisms of chemoattraction by which these cells are called to partake in or respond to neuroretinal injury remain largely ill defined. We therefore addressed this question with the widely used mouse model of oxygen-induced retinopathy (OIR) that mimics the destructive vasoproliferative phase of ocular neovascular diseases, such as DR (26) . A candidate receptor that could bridge neuronal stress to an immune response is neuropilin-1 (NRP-1). This single-pass transmembrane receptor, with a large 860-amino acid extracellular domain, has the unconventional ability to bind at least 2 structurally unrelated ligands (VEGF 165 and semaphorin 3A [SEMA3A]) via distinct sites (27) (28) (29) . While predominantly recognized for its role in neuronal or vascular guidance and as a coreceptor for VEGF 165 (30) , it has also been lo MPs were devoid of NRP-1 ( Figure 2B ).
NRP-1
+ myeloid cells localize to sites of pathological neovascularization in the retina. Given the pronounced influx of NRP-1 + macroImportantly, at each time point investigated, we observed a proportional increase in NRP-1 + MPs in OIR, with a rise of 37% at P10 (P = 0.0240) ( Figure 1D ), 61% at P14 (P = 0.0196) ( Figure  1G ), and 155% at P17 (P = 0.0058) ( Figure 1J ), suggesting that this subpopulation of NRP-1 + MPs was being recruited to the neuroretina during the progression of the disease. For all OIR experiments, weights of mouse pups were recorded (Supplemental Figure 3) to ascertain adequate metabolic health (35) .
In order to establish the role of MP-resident NRP-1 in retinopathy, we generated a myeloid-specific knockout of Nrp1 by intercrossing Nrp1-floxed mice with LysM-Cre mice (36) in the vitreous of patients suffering from active proliferative DR (PDR). Seventeen samples of undiluted vitreous were obtained from patients suffering from active PDR, and seventeen samples were obtained from control patients with nonvascular pathology. Detailed characteristics of patients are included in Table 1 . Control patients presented with nonvascular pathology and showed signs of non-diabetes-related retinal damage, such as tractional tension on vasculature ( Figure 5 , A and B, white arrows) secondary to fibrotic tissue and macular bulging ( Figure 5C ). In contrast, all retinas from patients with PDR showed signs of disc ( Figure 5D Figure 5G ). In addition, patients showed some evidence of macular edema due to compromised vascular barrier function, including cystoid formation due to focal coalescence of extravasated fluid ( Figure 5H ).
phage/microglia during OIR, we next sought to determine where these cells localize during the progression of disease. Immunofluorescence on retinal flat mounts revealed that NRP-1 + macrophage/microglia (colabeled with IBA1 and NRP-1) were intimately associated with nascent pathological tufts at P14 of OIR ( Figure 3 , A-C) as well as mature tufts at P17 of OIR ( Figure 4 , A-C). White arrows in Figure 3B and Figure 4B point to NRP-1 + MPs associated with preretinal tufts. NRP-1 was also expressed by endothelial cells on the endothelium of neovascular tufts as previously reported (21) . Consistent with data presented in Figure 1 Consistent with a role in PDR, ELISA-based detection of SEMA3A revealed a 5-fold higher concentration of the protein in the vitreous humors of patients with PDR when compared with that in the vitreous of control patients (P = 0.0132) ( Figure 5I ). Results were confirmed by Western blot analysis on equal volumes of vitreous, where SEMA3A (125-and 95-kDa isoforms) (38, 39) was elevated in patients with PDR ( Figure 5J ). Thus, upregulation of SEMA3A in the vitreous is induced in diabetic ocular pathology.
NRP-1 ligands are induced in the retinal ganglion cell layer during OIR. To obtain an accurate kinetic profile of expression of the 2 prominent ligands of NRP-1 in proliferative retinopathy, we investigated levels of Sema3a and Vegf message in the mouse model of OIR. Real-time quantitative PCR (RT-qPCR) on whole retinas revealed that Sema3a was robustly induced in OIR both during the hyperoxic (vasodegenerative) phase at P10 and the ischemic/ neovascular stage from P12 to P17 ( Figure 6A ). The observed induction occurred in both WT and LysM-Cre Nrp1 fl/fl retinas. Conversely, as expected, Vegf transcripts rose exclusively in the ischemic phase of OIR from P12 to P17 ( Figure 6B ). Importantly, Vegf was significantly less induced in LysM-Cre Nrp1 fl/fl retinas when compared with WT retinas (minimally increased at P12; P = 0.0451) and approximately 55% lower at P14 when compared WT OIR (P = 0.0003) ( Figure 6B ), indicative of a healthier retina.
We next performed laser capture microdissection followed by RT-qPCR on retinal layers in avascular zones to pinpoint the source of Sema3a and Vegf message in OIR ( Figure 4C ). Both Sema3a and Vegf were robustly induced in the ganglion cell layer, with Vegf also increasing in the inner nuclear layer ( Figure 6, D and E) . Thus, the source of both ligands is geographically consistent with the localization of retinal MPs (Figures 3 and 4) .
MPs do not proliferate in the retina after vascular injury. In order to determine whether the noted rise in NRP-1 + MPs was due to an influx from systemic circulation or an increase in MP proliferation within the retina, we investigated local retinal proliferation of these cells. Mice were systemically injected with BrdU at P13 (24 hours prior to sacrifice), and FACS analysis was carried out on retinas ( Figure 7A ) and spleens ( Figure 7B ). Within the retinas, Gr-1
+ MPs did not show significant proliferation (P = 0.4708). Considerably more proliferation was observed in spleens. No significant difference was observed between normoxia and OIR ( Figure 7C ). The lack of proliferation of MPs in the retinas suggests that the noted accretion of NRP-1 + MPs during retinopathy has a systemic or bone marrow-derived origin, as previously elegantly demonstrated for proangiogenic macrophages (40, 41) .
SEMA3A and VEGF 165 mobilize MPs via NRP-1. In light of the requirement of NRP-1 for myeloid cell mobilization to sites of vascular lesion (Figure 1) as well as the induction of the principal ligands of NRP-1 in retinopathy (Figures 5 and 6 ) and the likely systemic origin of these cells (Figure 7) , we sought to determine the propensity of these cues to provoke chemotaxis of MPs. Primary macrophage cultures were isolated from WT mice and subjected to a Transwell Boyden chamber migration assay. Both SEMA3A (100 ng/ml) (P < 0.0001) and VEGF 165 (50 ng/ml) (P = 0.0027) provoked macrophage chemotaxis to similar magnitudes as positive control MCP-1 (100 ng/ml) (P < 0.0001) (Figure 8, A and  B) . These data were validated by demonstrating that Y-27632, a selective inhibitor Rho-associated coiled coil-forming protein serine/threonine kinase (ROCK), abolished their chemotactic properties. ROCK is downstream of NRP-1 signaling (42) and is known to mediate monocyte migration (43) . VEGF migration was partially yet not significantly diminished, suggesting a contribution from alternate receptors such as VEGFR1 as recently reported (33) . Consistent with a role for NRP-1 in SEMA3A-and VEGF-mediated chemotaxis, macrophages from LysM-Cre 
Deficiency in myeloid-resident NRP-1 reduces vascular degeneration and pathological neovascularization in retinopathy.
Given the obligate role of NRP-1 in MP infiltration during the early stages of OIR (Figure 1 ), we next sought to determine the affect of myeloid cell-specific ablation of NRP-1 on the progression of disease. Upon exit from 75% O 2 at P12, LysM-Cre Nrp1 fl/fl mice showed significantly lower levels of retinal vaso-obliteration when compared with those of WT (P = 0.0011) and LysM-Cre Nrp1 +l+ (P < 0.0001) controls ( Figure 10, A and B) . This may be attributed to lower levels of IL-1β present in the retinas of LysM-Cre Nrp1 fl/fl mice (Supplemental Figure 6) . Importantly, at P17, when pathological neovascularization peaks (26) , deletion of myeloid-resident NRP-1 profoundly reduced avascular areas (~35% when compared with WT [P < 0.0001] and ~30% compared with LysM-Cre Nrp1 +l+ mice liposomes (i.e., vehicle control) had no affect on vascular sprouting, but clodronate liposomes reduced microvascular sprouting by approximately 60% (P = 0.0114 for LysM-Cre Nrp1 +/+ choroid and P = 0.0007 for LysM-Cre Nrp1 fl/fl choroid) ( Figure 9 , B-E). To verify whether NRP-1 + macrophages have a propensity to promote angiogenesis, we extracted peritoneal macrophages from LysM-Cre Nrp1 +/+ or LysM-Cre Nrp1 fl/fl mice and introduced them into choroid explant cultures that had been treated previously with clodronate liposomes and washed. LysM-Cre Nrp1 +/+ macrophages robustly potentiated microvascular sprouting by 50% to 100% when compared with macrophages from LysM-Cre Nrp1 The association of chronic low-grade inflammation with the progression of DR (5) and the link between neonatal infections and ROP (9, 44) underscores the potential therapeutic worth of antiinflammatory drugs in treatment of proliferative retinopathies (45) , yet toxicity remains a concern especially in pediatric populations. This is observed with prolonged use of intravitreal glucocorticoids (widely used for diabetic macular edema), which leads to increased cataract formation and elevated intraocular pressure (46) . Hence, in order to improve safety profiles of current antiinflammatory treatment paradigms, it will be necessary to provide a honed intervention that specifically targets damaging sterile neuroinflammation.
The identification of the SEMA3A/NRP-1 axis in chemoattraction of destructive MPs in retinopathy may provide such a target. In contrast to VEGF, which is essential for retinal homeostasis, expression of SEMA3A in healthy mature retinas is limited (20) . However, in diabetes and OIR, retinal ganglion neurons, which are in intimate proximity with retinal vessels, generate significant amounts of this cue (20, 21) . In addition to a role in local MP chemotaxis, SEMA3A also directly affects microvessels (47) and may directly induce endothelial apoptosis and promote cytoskeleton remodeling (47) (48) (49) (50) . Specifically in the retina, SEMA3A hinders physiological vascular regeneration in OIR (21) and provokes pathological compromise of barrier function in DR (20) . Hence, therapeutic neutralization of SEMA3A may provide a multifaceted advantage over current intravitreally delivered compounds and may have limited toxicity, given that its expression is typically restricted to embryogenesis (51) . Our data also raise the possibility that, beyond direct influence on angiogenesis and barrier function (52) , the mode of action of current anti-VEGF therapies may also in part involve limiting MP-induced lesions to the neuroretina.
Together, the findings presented in this study establish a basis for future investigations on the role of NRP-1 + MPs and their ligands in CNS disorders characterized by excessive neuroinflammation. Understanding the signals that influence neuroimmune interplay may provide valuable therapeutic insight for 
Therapeutic intravitreal administration of soluble NRP-1 reduces MP infiltration and pathological neovascularization in retinopathy.
To determine the translational potential of our findings, we next used a soluble recombinant mouse NRP-1 (rmNRP-1) ( Figure  11A ) as a trap to sequester OIR-induced ligands of NRP-1. A single intravitreal injection of rmNRP-1 at P12 lead to a 30% reduction at P14 (P = 0.0282) in the number of microglia present in retinas subjected to OIR ( Figure 11B ). This finding attests to the potency of soluble NRP-1 (1 μl of 500 μg/ml) to compromise microglial mobilization. Intravitreal administration of soluble NRP-1 provoked a significant approximate 40% decrease in pathological preretinal angiogenesis when compared with that of vehicle-injected controls (P = 0.0025) (Figure 11, C and D) . Together, these data suggest that neutralization of ligands of NRP-1 is an effective strategy to reduce destructive neovascularization in retinopathy.
Discussion
Although the contribution of MPs to ocular neovascular diseases such as DR has been established for over a decade, knowledge of the mechanisms by which they are locally recruited to areas of tissue damage and partake in the disease process remains limited. Here, we demonstrate that stressed retinal neurons (19, 21) and neural tissue have the inherent ability to modulate the local innate immune response via unconventional chemotactic agents, such as model serves as a proxy to human ocular neovascular diseases such as DR, which is characterized by a late phase of destructive pathological angiogenesis (54, 55) . Upon return to room air, hypoxia-driven neovascularization develops from P14 onward (26). We enucleated eyes at different time points and dissected the retinas for FACS analysis or mRNA analysis as described below. In other experiments, dissected retinas were flat mounted and incubated overnight with fluoresceinated isolectin B4 (1:100) in 1 mM CaCl 2 to determine extent of avascular area or neovascularization area at P17 using ImageJ and the SWIFT-neovascularization method (56) .
FACS of digested retinas
Retinas from WT or LysM-Cre Nrp1 fl/fl mice were homogenized and incubated in a solution of 750 U/ml DNase I (Sigma-Aldrich) and 0.5 mg/ml the design of selective antiinflammatory treatments to counter destructive neuroinflammation.
Methods
Animals C57BL/6 WT mice were purchased from The Jackson Laboratory. LysMCre (Lyz2 ) and their fostering mothers (CD1, Charles River) were exposed to 75% O 2 from P7 to P12 and returned to room air (53). This To ascertain that SEMA3A and VEGF were stimulating macrophage chemotaxis, cells were pretreated with the selective ROCK inhibitor Y-27632 (100 μg/ml), which abolished chemotaxis. (C) Macrophages from LysM-Cre Nrp1 fl/fl mice were unresponsive to SEMA3A or VEGF but responsive to MCP-1. Data are expressed as a fold change relative to control (nontreated cells); horizontal bars represent mean value of the fold change, and dots represent individual fold changes; n = 6-22; **P < 0.01, ***P < 0.001. Scale bars: 100 μm.
Analysis of BrdU incorporation
The staining was performed on the retinal cells from P14 WT mice. Samples were obtained as described above. Extracellular staining was performed as described above (CD45. 
Vitrectomy
All patients previously diagnosed with PDR were followed and operated by a single vitreoretinal surgeon (F.A. Rezende). Control patients underwent surgical treatment for nonvascular pathology (epiretinal membrane or macular hole) by the same surgeon. In an operating room setting, patients underwent surgery under local retro/peribulbar anesthesia. A 5% povidone-iodine solution was used to clean the periocular skin, and topical instillation into the eye and within the cul-de-sac was left in place for 5 minutes. Three-port 25-gauge transconjunctival pars plana vitrectomy was performed through 25-gauge valved cannulas (Alcon). Under microscope visualization using a wide-angle viewing system (Resight, Zeiss), undiluted vitreous was collected with a 25-gauge vitrector. After vitreous biopsy, the infusion line was opened, and vitrectomy and membrane collagenase D (Roche) for 15 minutes at 37°C with gentle shaking. Homogenates were then filtered with a 70-μm cell strainer and washed in PBS and 3% FBS. Spleen samples were homogenized and incubated with 1 mg/ml collagenase D for 10 minutes at 37°C. Homogenates were washed in PBS and 3% FBS, and the pellets were resuspended and incubated in lysis buffer (10 mM KCHO 3 ; 150 mM NH 4 Cl; 0.1 mM EDTA) for 5 minutes at room temperature. Cell suspensions (retina or spleen) were incubated with LEAF purified antimouse CD16/32 (Biolegend) for 15 minutes at room temperature to block Fc receptors. Cells were then incubated for 30 minutes at room temperature with the following antibodies: FITC anti-mouse/human CD11b (Biolegend), PE/CY7 anti-mouse Ly-6G/Ly-6C (Gr-1; Biolegend), Pacific Blue anti-mouse F4/80 (Biolegend), 7AAD (BD Biosciences), and anti-mNRP-1 allophycocyanin-conjugated rat IgG2A (R&D Systems) or allophycocyanin-conjugated rat IgG2A isotype control (R&D Systems).
For analysis of CX3CR1 and CD45 expression, additional extracellular staining was performed using the above-mentioned antibodies supplemented with Alexa Fluor 700 anti-mouse CD45.2 (Biolegend) and anti-mouse CX3CR1 phycoerythrin-conjugated goat IgG (R&D Systems) or phycoerythrin-conjugated goat IgG isotype control. FACS was performed on a LSRII (BD Biosciences) device, and data were analyzed using FlowJo software (version 7.6.5).
BrdU injections
WT mice subjected to OIR or kept in normoxic conditions were injected intraperitoneally with 5-bromo-2-deoxyuridine (BrdU; SigmaAldrich) at the dose of 1 mg per mouse dissolved in PBS at P13. was washed with 5 ml PBS plus 3% FBS for 2 minutes. Then, the harvested cells were centrifuged for 5 minutes at 100 g, resuspended in medium (DMEM F12 plus 10% FBS and 1% streptomycin/penicillin), and plated. After 1 hour of culture at 37°C under a 5% CO 2 atmosphere, the medium was changed and cells were cultured for the next 24 hours in the same conditions before use in Transwell migration assay.
Transwell migration assay
Migration assays were performed in 24-well plates with 8-μm pore inserts. Primary peritoneal macrophages (5 × 10 5 cells) resuspended in 200 μl medium (DMEM F12 plus 10% FBS and 1% streptomycin/ penicillin) were added to the upper chamber. 800 μl medium, with or without migratory factors, MCP-1 (100 ng/ml), SEMA3A (100 ng/ml), and VEGF 165 (50 ng/ml), was added to the lower chamber. Cells were allowed to migrate through the insert membrane overnight at 37°C under a 5% CO 2 atmosphere. In some experiments, cells were first pretreated with Y-27632 (Sigma-Aldrich), selective ROCK inhibitor (100 μg/ml), for 1 hour at 37°C. The inserts were then washed with PBS, and nonmigrating cells were swabbed from the upper surface of the insert membrane with cotton buds. Then, the membranes with migrated cells were fixed with 4% paraformaldehyde for 20 minutes, washed twice with PBS, and mounted on the slide. The cells were stained using mounting medium with DAPI (Vector Laboratories Inc.). Then, 9 random fields per each membrane were photographed using an inverted fluorescence microscope at ×20 magnification, and the cells were counted using ImageJ software.
Choroidal explants and microvascular sprouting assay
The ex vivo choroid explant analysis and quantification of microvascular sprouting were performed as described previously (57) . Briefly, choroids from LysM-Cre Nrp1 +/+ and LysM-Cre Nrp1 fl/fl mice (n = 6
for each condition) were dissected shortly after enucleating eyes. After plating segmented choroids into 24-well tissue culture plates and covering with Matrigel (BD Biosciences), samples were treated with EGM-2 medium, EGM-2 medium with PBS filled liposome, or EGM-2 medium with dichloromethylenediphosphonic acid disodium peeling was performed in the usual fashion to treat diabetic vitreous hemorrhage and tractional retinal detachment. This was followed by panretinal endolaser photocoagulation, fluid-air exchange, and intravitreal anti-VEGF injection.
Quantification of SEMA3A protein by ELISA Vitreous samples were frozen on dry ice immediately after biopsy and stored at -80°. Samples were centrifuged at 15,000 g for 5 minutes at 4°C prior to analysis. SEMA3A levels were quantified in supernatants using ELISAs following manufacturer's instructions (USCN Life Science Inc.).
Assessment of SEMA3A protein levels by Western blot Equal volumes of vitreous fluid (20 μl) from PDR and control patients were assessed by standard SDS-PAGE technique for the presence of SEMA3A (Abcam).
Real-time PCR analysis RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) and digested with DNase I to prevent amplification of genomic DNA. Reversed transcription was performed using M-MLV reverse transcriptase (Life Technologies), and gene expression was analyzed using SYBR Green (Bio-Rad) in an ABI Biosystems Real-Time PCR machine. β-Actin was used as a reference gene.
Immunohistochemistry
For visualization of pan-retinal vasculature, flat-mount retinas were stained with rhodamine-labeled Griffonia (Bandeiraea) Simplicifolia Lectin I (Vector Laboratories Inc.) in 1 mM CaCl 2 in PBS for retinal vasculature and anti-mouse/rat NRP-1 antibody (goat IgG; R&D Systems) and IBA1 (rabbit polyclonal; Wako).
Primary peritoneal macrophages culture
Adult WT or LysM-Cre Nrp1 fl/fl mice were anesthetized with 2% isoflurane in oxygen 2 l/min and then euthanized by cervical dislocation. Then, a small incision in abdominal skin of mouse was performed. Skin was pulled to each size of the mouse, and the peritoneal cavity 
